AstraZeneca plc (LON:AZN) received a GBX 4,000 ($49.98) price target from Goldman Sachs Group Inc. in a report issued on Friday. The brokerage currently has a a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s target price would suggest a potential downside of 8.37% from the company’s previous close.

Several other research analysts also recently weighed in on AZN. BNP Paribas downgraded shares of AstraZeneca plc to a “neutral” rating and set a GBX 5,200 ($64.97) price target for the company. in a research report on Wednesday, September 14th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, November 9th. HSBC restated a “hold” rating and set a GBX 4,700 ($58.72) price target on shares of AstraZeneca plc in a research report on Thursday, August 11th. Beaufort Securities restated a “hold” rating on shares of AstraZeneca plc in a research report on Friday. Finally, Societe Generale set a GBX 7,000 ($87.46) price target on shares of AstraZeneca plc and gave the stock a “buy” rating in a research report on Thursday, September 8th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of GBX 4,947.72 ($61.82).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4350.00 on Friday. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The company’s market cap is GBX 55.03 billion. The stock’s 50 day moving average is GBX 4,806.39 and its 200 day moving average is GBX 4,565.34.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.